Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
CHE Stock Forecast 2026-2027
$384.61
Current Price
$5.29B
Market Cap
Buy 1
Hold 3
Sell 0
Wall St Analyst Ratings
Distance to CHE Price Targets
+30.0%
To High Target of $500.00
+13.4%
To Median Target of $436.00
+4.0%
To Low Target of $400.00
CHE Price Momentum
-0.8%
1 Week Change
+1.8%
1 Month Change
-33.9%
1 Year Change
-10.1%
Year-to-Date Change
-35.2%
From 52W High of $593.80
+5.3%
From 52W Low of $365.21
📊 TOP ANALYST CALLS
Did CHE Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Chemed Corp is one of their latest high-conviction picks.
Latest CHE Stock Price Targets & Analyst Predictions
Based on our analysis of 6 Wall Street analysts, CHE has a neutral consensus with a median price target of $436.00 (ranging from $400.00 to $500.00). The overall analyst rating is Buy (7.0/10). Currently trading at $384.61, the median forecast implies a 13.4% upside. This outlook is supported by 1 Buy, 3 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Michael Wiederhorn at Oppenheimer, projecting a 30.0% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CHE Analyst Ratings
1
Buy
3
Hold
0
Sell
CHE Price Target Range
Low
$400.00
Average
$436.00
High
$500.00
Current: $384.61
Latest CHE Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CHE.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Feb 27, 2026 | RBC Capital | Ben Hendrix | Sector Perform | Downgrade | $422.00 |
| Feb 27, 2026 | Oppenheimer | Michael Wiederhorn | Outperform | Maintains | $500.00 |
| Jan 22, 2026 | Jefferies | Brian Tanquilut | Hold | Downgrade | $475.00 |
| Nov 10, 2025 | RBC Capital | Ben Hendrix | Outperform | Maintains | $572.00 |
| Sep 10, 2025 | B of A Securities | Joanna Gajuk | Buy | Maintains | $595.00 |
| Sep 2, 2025 | Jefferies | Brian Tanquilut | Buy | Upgrade | $550.00 |
| Jul 31, 2025 | Oppenheimer | Michael Wiederhorn | Outperform | Maintains | $580.00 |
| Jul 31, 2025 | RBC Capital | Ben Hendrix | Outperform | Maintains | $589.00 |
| Jul 25, 2025 | Jefferies | Brian Tanquilut | Hold | Initiates | $500.00 |
| Jun 30, 2025 | B of A Securities | Joanna Gajuk | Buy | Maintains | $650.00 |
| Jun 30, 2025 | RBC Capital | Ben Hendrix | Outperform | Maintains | $640.00 |
| Apr 28, 2025 | RBC Capital | Ben Hendrix | Outperform | Maintains | $674.00 |
| Mar 14, 2025 | RBC Capital | Ben Hendrix | Outperform | Maintains | $667.00 |
| Nov 5, 2024 | RBC Capital | Ben Hendrix | Outperform | Maintains | $633.00 |
| May 21, 2024 | RBC Capital | Ben Hendrix | Outperform | Maintains | $697.00 |
| Mar 4, 2024 | RBC Capital | Ben Hendrix | Outperform | Maintains | $712.00 |
| Feb 29, 2024 | Oppenheimer | Michael Wiederhorn | Outperform | Maintains | $650.00 |
| Jan 17, 2024 | Oppenheimer | Michael Wiederhorn | Outperform | Maintains | $625.00 |
| Oct 30, 2023 | RBC Capital | Ben Hendrix | Outperform | Maintains | $604.00 |
| Jul 31, 2023 | RBC Capital | Ben Hendrix | Outperform | Maintains | $576.00 |
Chemed Corporation (CHE) Competitors
The following stocks are similar to Chemed Corp based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Chemed Corporation (CHE) Financial Data
Chemed Corporation has a market capitalization of $5.29B with a P/E ratio of 21.0x. The company generates $2.53B in trailing twelve-month revenue with a 10.5% profit margin.
Revenue growth is -0.1% quarter-over-quarter, while maintaining an operating margin of +16.6% and return on equity of +25.3%.
Valuation Metrics
Market Cap
$5.29B
Enterprise Value
$5.36B
P/E Ratio
21.0x
PEG Ratio
-2.1x
Price/Sales
2.1x
Growth & Margins
Revenue Growth (YoY)
-0.1%
Gross Margin
+35.2%
Operating Margin
+16.6%
Net Margin
+10.5%
EPS Growth
-15.0%
Financial Health
Cash/Price Ratio
+1.4%
Current Ratio
1.1x
Debt/Equity
14.7x
ROE
+25.3%
ROA
+13.4%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Chemed Corporation (CHE) Business Model
About Chemed Corporation
What They Do
Provides healthcare and plumbing services.
Business Model
The company operates through two segments: VITAS Healthcare, which offers hospice and palliative care services, and Roto-Rooter, which provides plumbing and related maintenance services. This diversified approach allows Chemed Corporation to generate revenue from both healthcare and home services, capitalizing on the essential nature of these offerings.
Additional Information
Founded in 1970 and headquartered in Cincinnati, Ohio, Chemed Corporation has established a strong market presence in both sectors. The company's dual-segment structure offers resilience against market fluctuations, appealing to investors looking for stability in their portfolios.
Company Information
Sector
Healthcare
Industry
Medical Care Facilities
Employees
15,695
CEO
Mr. Kevin J. McNamara
Country
United States
IPO Year
1973
Website
www.chemed.comChemed Corporation (CHE) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Analysts Estimate Chemed (CHE) to Report a Decline in Earnings: What to Look Out for
Chemed (CHE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Apr 16, 2026
By Zacks Equity Research
Tale of the Tape
Latest News
Quick Summary
Chemed (CHE) is not expected to meet earnings expectations in its upcoming report due to a lack of key indicators for a potential earnings beat.
Why It Matters
Chemed's lack of essential factors for a potential earnings beat signals possible underperformance, which may negatively impact stock prices and investor sentiment.
Source: Zacks Investment Research
Market Sentiment:
Negative
Chemed Corporation Announces a Five-Year $450 Million Amended and Restated Credit Agreement
7 days ago
Quick Summary
Chemed Corporation (NYSE:CHE) has amended its credit facility with JPMorgan Chase Bank, enhancing its financial arrangements.
Why It Matters
Chemed's new credit agreement may enhance liquidity and financial flexibility, potentially impacting its growth strategy and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
New Strong Sell Stocks for April 15th
5 days ago
Quick Summary
CPAC, EPC, and CHE were added to the Zacks Rank #5 (Strong Sell) List on April 15, 2026, indicating a negative outlook for these stocks.
Why It Matters
CPAC, EPC, and CHE being added to the Zacks Rank #5 signifies potential underperformance, prompting caution for investors considering these stocks.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
Roto-Rooter Services Company completed two acquisitions for a total of $20.6 million in Fort Worth, Texas, and San Francisco, California, on March 31, 2026.
Why It Matters
Roto-Rooter's acquisitions may enhance market presence and revenue, potentially boosting shareholder value and signaling growth strategy effectiveness.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Chemed To Report First Quarter 2026 Earnings April 23, Related Conference Call To Be Held On April 24
19 days ago
Quick Summary
Chemed Corporation (NYSE: CHE) will release Q1 2026 financial results on April 23, 2026, after market close, followed by a conference call at 10 a.m. the same day.
Why It Matters
Chemed Corporation's upcoming financial results announcement and conference call may influence stock performance and investor sentiment, providing insights into the company's growth and profitability.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Chemed (CHE) reported earnings 30 days ago; investors should monitor upcoming developments and performance for potential impacts on the stock.
Why It Matters
Chemed's recent earnings report can influence stock performance and investor sentiment, impacting future price movements and investment decisions.
Source: Zacks Investment Research
Market Sentiment:
Negative
Frequently Asked Questions About CHE Stock
What is Chemed Corporation's (CHE) stock forecast for 2026?
Based on our analysis of 6 Wall Street analysts, Chemed Corporation (CHE) has a median price target of $436.00. The highest price target is $500.00 and the lowest is $400.00.
Is CHE stock a good investment in 2026?
According to current analyst ratings, CHE has 1 Buy ratings, 3 Hold ratings, and 0 Sell ratings. The stock is currently trading at $384.61. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CHE stock?
Wall Street analysts predict CHE stock could reach $436.00 in the next 12 months. This represents a 13.4% increase from the current price of $384.61. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Chemed Corporation's business model?
The company operates through two segments: VITAS Healthcare, which offers hospice and palliative care services, and Roto-Rooter, which provides plumbing and related maintenance services. This diversified approach allows Chemed Corporation to generate revenue from both healthcare and home services, capitalizing on the essential nature of these offerings.
What is the highest forecasted price for CHE Chemed Corporation?
The highest price target for CHE is $500.00 from Michael Wiederhorn at Oppenheimer, which represents a 30.0% increase from the current price of $384.61.
What is the lowest forecasted price for CHE Chemed Corporation?
The lowest price target for CHE is $400.00 from at , which represents a 4.0% increase from the current price of $384.61.
What is the overall CHE consensus from analysts for Chemed Corporation?
The overall analyst consensus for CHE is neutral. Out of 6 Wall Street analysts, 1 rate it as Buy, 3 as Hold, and 0 as Sell, with a median price target of $436.00.
How accurate are CHE stock price projections?
Stock price projections, including those for Chemed Corporation, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 20, 2026 11:38 AM UTC